Companion Diagnostics: Page 2

Foundation Medicine enters companion diagnostic collaboration with Merck KGaA

By LabPulse.com staff writers

The agreement builds on a partnership the firms entered in 2020 to accelerate the development of novel targeted therapies.

June 5, 2023

Tempus granted FDA premarket approval for colorectal cancer CDx

By LabPulse.com staff writers

The NGS test detects substitutions (single nucleotide variants (SNVs) and multi-nucleotide variants (MNVs) and insertion and deletion alterations (INDELs) in 648 genes, as well as microsatellite instability (MSI) status.

May 1, 2023

Veracyte announces data for prostate cancer classifier in micrometastatic disease

By LabPulse.com staff writers

The published data show that the Decipher Prostate scores for patients with high-risk and very high-risk disease were highly correlated with the upstaging predictions by a clinically-validated algorithm.

April 17, 2023

Foundation Medicine to collaborate with Bristol Myers Squibb on companion diagnostic for solid tumors

By LabPulse.com staff writers

The FoundationOne CDx test would be used in identifying patients likely to respond to treatment with repotrectinib if both the treatment and the test are approved.

April 11, 2023

Oncocyte announces results for gene expression test in colorectal cancer clinical trial

By LabPulse.com staff writers

The results, published in Clinical Cancer Research, show that DetermaIO identified more patients who were potentially responsive to immune checkpoint inhibitor treatment than current biomarkers identified.

April 10, 2023

AmoyDx PLC Panel gets Japanese approval as companion diagnostic for NSCLC

By LabPulse.com staff writers

The AmoyDx PLC Panel has been approved in Japan for the identification of activating alterations in seven driver genes, including RET, to be used in identifying patients whose NSCLC is likely to respond to treatment with selpercatinib.

March 27, 2023

Servier, Qiagen partner to develop companion diagnostic test for AML

By LabPulse.com staff writers

Under a master collaboration agreement, Qiagen will develop and validate a real-time PCR-based in vitro diagnostic test that can be used to detect IDH1 gene mutations in whole blood and bone marrow aspirates in AML.

March 9, 2023

UnitedHealthcare to offer coverage for Foundation Medicine CDx tests for multiple cancer types

By LabPulse.com staff writers

Both tests can be used to identify patients who may benefit for treatment from specific targeted therapies. UnitedHealthcare’s coverage for the tests will be effective beginning April 1, 2023.

February 9, 2023

Roche, Janssen expand collaboration to develop CDx tests for targeted therapies

By LabPulse.com staff writers

The collaboration involves numerous companion diagnostics technologies, including immunohistochemistry, digital pathology, next generation sequencing, PCR, and immunoassays.

February 9, 2023

Guardant360 CDx breast cancer liquid biopsy test receives FDA approval as companion diagnostic

By LabPulse.com staff writers

The Guardant360 CDx blood test uses genomic profiling to identify patients with ESR1 mutations who may benefit from Orserdu therapy.

January 30, 2023

Qiagen obtains FDA approval for NSCLC companion diagnostic assay

By LabPulse.com staff writers

Therascreen KRAS is a tissue-based polymerase chain reaction (PCR) assay designed to identify NSCLC patients likely to respond to treatment with Mirati Therapeutics’ Krazati (adagrasib).

December 13, 2022

Invivoscribe files for FDA approval for acute myeloid leukemia CDx

By LabPulse.com staff writers

The filing supports Daiichi Sankyo's new drug application (NDA) for quizartinib for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML. The application has been granted Priority Review status by the FDA.

October 24, 2022

Previous Page

Page 2 of 13

Next Page